A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.

Luca Rastelli,Maqbool Mohsin,Ann Marie Rossi,Enrique Alvarez Sotomayor,Lawrence Iben,Ada Vaill,Matthew Welsch,Rizwan Romee,Anna Bunin

A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.

2020

Luca Rastelli
Maqbool Mohsin
Ann Marie Rossi
Enrique Alvarez Sotomayor
Lawrence Iben
Ada Vaill
Matthew Welsch
Rizwan Romee
Anna Bunin

8523Background: Cytokine-induced memory-like (CIML) NK cells differentiate after a brief preactivation with interleukin-12 (IL-12), IL-15, and IL-18 and exhibit enhanced responses to cytokine or ac...

Keywords:

Multiple myeloma
Cellular engineering
CD38
Cytokine
Pathology
Ex vivo
Antibody
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations